Blood screening for MGUS: preventing progression with PROMISE
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, gives us an update on the exciting PROMISE study, which performs a…
Related Articles
Interim results from the PROMise study of OPN-2853 with ruxolitinib in myelofibrosis
Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the interim analysis of the PROMise study (ISRCTN12451433),…
The current standard of care for CTCL
In this video, Pierluigi Porcu, MD, Sidney Kimmel Cancer Center, Philadelphia, PA, outlines the current standard of care (SoC) for cutaneous T-cell lymphoma (CTCL). Dr…
Final analysis from a Phase I trial of asciminib in T315I-mutated CML-CP
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, briefly comments on the final analysis of a Phase…
Multiple Myeloma – VJHemOnc
In association with our world-leading Editorial Board, VJHemOnc bring you the latest updates in multiple myeloma, directly from the experts.
Organ response data from the SWOG S1702 trial of isatuximab in relapsed AL amyloidosis
Terri Parker, MD, Yale University School of Medicine, New Haven, CT, briefly outlines the updated results of the Phase II SWOG S1702 trial (NCT03499808), a…
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…
ENERGIZE-T: a Phase III study of mitapivat in transfusion-dependent alpha- or beta-thalassemia
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, presents the updated results of the ENERGIZE-T study (NCT04770779), a Phase III open-label double-blind placebo-controlled study…
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)…
Findings from a Phase I trial of the BTK degrader NX-5948 in B-cell malignancies
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on updated findings from a Phase I trial (NCT05131022) investigating the BTK degrader NX-5948…
Myeloid mutations in ALL and their role in identifying those at risk of secondary malignancies
Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, comments on the presence of myeloid mutations in acute lymphoblastic leukemia (ALL). She highlights that…